Zepbound outperformed Wegovy for weight loss in a new clinical trial funded by Eli Lilly & Co., Zepbound's maker.
Novo Nordisk's Lotte Bjerre Knudsen says her determination is a key part of the success, but she also stays humble.
The proposed buyout of contract drug manufacturer Catalent won’t raise competition concerns, the European Commission said.
They are currently approved for treating diabetes, obesity and those with a history of cardiovascular disease in people who ...
In a report released today, Jo Walton from UBS maintained a Hold rating on Novo Nordisk (0QIU – Research Report), with a price target of ...
Weight-loss drugs like Ozempic seem like a miracle. But they've also created a gold rush for online scammers and hucksters.
Joe Breen, 38, is one of thousands of people whose experiences with GLP-1s such as Ozempic and Wegovy have radically changed their relationship with alcohol. Are these drugs the future for treating ...
Eli Lilly will launch Mounjaro in India in 2025. The drug treats type 2 diabetes and obesity. Lilly received marketing authorization in July. It is working on additional approvals. Mounjaro's global ...
According to a sneak peek of the data from one of Eli Lilly's (NYSE: LLY) late-stage clinical trials, the cardiometabolic ...
Eli Lilly and Company announced earlier this week that its popular obesity drug, Zepbound (tirzepatide) outperformed rival ...